AR051457A1 - Indazoles, benzisoxazoles y benzisotiazoles, procedimiento para prepararlos, composiciones farmaceuticas y su uso como agentes estrogenicos - Google Patents
Indazoles, benzisoxazoles y benzisotiazoles, procedimiento para prepararlos, composiciones farmaceuticas y su uso como agentes estrogenicosInfo
- Publication number
- AR051457A1 AR051457A1 ARP050104313A ARP050104313A AR051457A1 AR 051457 A1 AR051457 A1 AR 051457A1 AR P050104313 A ARP050104313 A AR P050104313A AR P050104313 A ARP050104313 A AR P050104313A AR 051457 A1 AR051457 A1 AR 051457A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- group
- substituted
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los compuestos son moduladores de los receptores de estrogeno. Reivindicacion 1: Un compuesto de formula (1), o una sal de adicion ácida o una forma estereoisomérica del mismo; caracterizado porque: R1 es hidrogeno o un C1-6 alquilo, C3-6 cicloalquilo, trifluorometilo, -N=NCR5R6, -SO2NR7R8, fenilo, fenilC1-3alquilo o C1-3 alquilo sustituido por un radical heterocíclico saturado, donde el fenilo es insustituido o sustituido por al menos un sustituyente seleccionado dentro del grupo consistente en un hidroxilo, un halogeno, nitro, un ciano, un C1-3 alquilo, un C1-3 alcoxi y un trifluorometilo; R1 puede estar también una sal; cada uno de R2 y R3 es independientemente un grupo hidrogeno o un hidroxilo, halogeno, nitro, ciano, C1- 6 alquilo, C3-6 cicloalquilo, C1-6 alcoxi, trifluorometilo, -NR7R8, -CONR7R8, -COR9 o -CO2R9; R2 puede ser también un fenilo o un heterociclo saturado o insaturado, donde el fenilo es insustituido o sustituido por al menos un sustituyente seleccionado dentro del grupo consistente en hidroxilo, halogeno, nitro, ciano, C1-3 alquilo, C1-3 alcoxi, trifluorometilo un radical heterocíclico saturado; X es O, S, SO, SO o NR4; R4 es hidrogeno o un grupo C1-6 alquilo, C3-6 cicloalquilo, fenilo, fenilC1-3alquilo, C1-3 alquilo sustituido por un radical heterocíclico saturado, un grupo -COR7, -CO2R7 o -SO2NR7R8, donde el fenilo es insustituido o sustituido por al menos un sustituyente seleccionado dentro del grupo consistente en un hidroxilo, un halogeno, un nitro, un ciano, un C1-3 alquilo, un C1-3 alcoxi, un trifluorometilo, un fenilC1-3alquilo y un fenilC1-3alcoxi; Y es un enlace directo, O, S, SO, SO2, NR4, CO, -(CR10R11)n- o -R10C=CR11-; cada uno de R5, R6, R7 y R8 es independientemente hidrogeno o un grupo C1-6 alquilo o C3-6 cicloalquilo; R9 es hidrogeno, C1-6 alquilo, fenilo o un radical heterocíclico saturado o insaturado, donde el fenilo es insustituido o sustituido por al menos un sustituyente seleccionado dentro del grupo consistente en hidroxilo, halogeno, nitro, ciano, C1-3 alquilo, C1-3 alcoxi, trifluorometilo y un radical heterocíclico saturado; cada uno de R10 y R11 es independientemente hidrogeno o un grupo ciano, C1-6 alquilo, -CO-fenilo, - CO(radical heterocíclico insaturado) o -CONR7R8, donde el fenilo es insustituido o está sustituido por al menos un sustituyente seleccionado dentro del grupo consistente en hidroxilo, halogeno, nitro, ciano, C1-3 alquilo, C1-3 alcoxi y trifluorometilo; n es 1 o 2; A es C3-15 cicloalquilo, C3-15 cicloalqueno, fenilo o naftilo, donde el cicloalquilo o el cicloalqueno está insustituido o sustituido por al menos un C1-6 alquilo, y donde el fenilo o el naftilo es insustituido o sustituido por al menos un sustituyente seleccionado dentro del grupo consistente en hidroxilo, halogeno, nitro, ciano, C1-3 alquilo, C1-3 alcoxi y trifluorometilo; cuando X es NR4, Y y R2 junto con el anillo de indazolo que los lleva pueden formar también un 1H-pirano[4,3,2-cd]indazol; proveyéndose que: cuando X es O, S o NR4, R1 es hidrogeno o C1-6 alquilo, C3-6 cicloalquilo o trifluorometilo, e Y es un enlace directo, A no es fenilo opcionalmente sustituido o naftilo opcionalmente sustituido; cuando X es NR4 donde R4 es H o C1-6 alquilo y R1O es 6-OCH3, Y no es CO; cuando X es O, R1O es 6-OH o 6-OCH3, Y es un enlace directo y A es ciclopentilo, (R2, R3) o (R3,R2) es diferente de (H, Cl) en la posicion 4,5; cuando X es O, R1O es 6-OH, R2 y R3 son H e Y es CH=CH, A no es fenilo o 4-metoxifenilo; cuando X es SO2, A es fenilo y R1O es 5- o 6-OCH3, (R2, R3) o (R3, R2) es diferente de (H, OCH3) en la posicion 6- o 5-.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04292439A EP1647549A1 (en) | 2004-10-14 | 2004-10-14 | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051457A1 true AR051457A1 (es) | 2007-01-17 |
Family
ID=34931452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050104313A AR051457A1 (es) | 2004-10-14 | 2005-10-14 | Indazoles, benzisoxazoles y benzisotiazoles, procedimiento para prepararlos, composiciones farmaceuticas y su uso como agentes estrogenicos |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7977364B2 (es) |
| EP (2) | EP1647549A1 (es) |
| JP (1) | JP5047801B2 (es) |
| KR (1) | KR20070109976A (es) |
| CN (1) | CN101080395B (es) |
| AP (1) | AP2007003960A0 (es) |
| AR (1) | AR051457A1 (es) |
| AT (1) | ATE512952T1 (es) |
| AU (1) | AU2005293509B2 (es) |
| BR (1) | BRPI0516851A (es) |
| CA (1) | CA2582180C (es) |
| ES (1) | ES2368203T3 (es) |
| IL (1) | IL182047A (es) |
| MA (1) | MA28928B1 (es) |
| MX (1) | MX2007004372A (es) |
| NO (1) | NO20071922L (es) |
| NZ (1) | NZ554279A (es) |
| RU (1) | RU2402536C2 (es) |
| SG (1) | SG158886A1 (es) |
| TN (1) | TNSN07138A1 (es) |
| TW (1) | TW200619202A (es) |
| UA (1) | UA90280C2 (es) |
| WO (1) | WO2006040351A1 (es) |
| ZA (1) | ZA200702690B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1647549A1 (en) * | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
| JP4965270B2 (ja) * | 2007-01-16 | 2012-07-04 | 出光興産株式会社 | アダマンチルカルボニル基含有芳香族ジオール、その誘導体及びそれらの製造方法 |
| FR2913019A1 (fr) * | 2007-02-23 | 2008-08-29 | Cerep Sa | Composes heterocycliques comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire |
| GB0704407D0 (en) | 2007-03-07 | 2007-04-18 | Glaxo Group Ltd | Compounds |
| GB0803017D0 (en) | 2008-02-19 | 2008-03-26 | Glaxo Group Ltd | Compounds |
| DK2710007T3 (da) * | 2011-05-17 | 2020-01-27 | Principia Biopharma Inc | Kinasehæmmere |
| US20150018398A1 (en) * | 2013-07-15 | 2015-01-15 | The Regents Of The University Of California | Methods of using estrogen receptor-beta ligands as radiation mitigators |
| DE102015012050A1 (de) * | 2015-09-15 | 2017-03-16 | Merck Patent Gmbh | Verbindungen als ASIC-Inhibitoren und deren Verwendungen |
| CN109111407A (zh) * | 2017-06-23 | 2019-01-01 | 江苏恩华药业股份有限公司 | 一种苯并异恶唑类化合物衍生物及其应用 |
| BR112020002265A2 (pt) | 2017-08-01 | 2020-07-28 | Theravance Biopharma R&D Ip, Llc | compostos pirazólicos e triazólicos bicíclicos como inibidores de jak quiinase |
| CN110117278B (zh) * | 2018-02-07 | 2022-07-19 | 石家庄以岭药业股份有限公司 | 烷氧基苯并五元(六元)杂环胺类化合物及其药物用途 |
| JP2022518741A (ja) | 2019-01-23 | 2022-03-16 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ＪＡＫキナーゼ阻害剤としてのイミダゾ［１，５－ａ］ピリジン、１，２，４－トリアゾロ［４，３－ａ］ピリジンおよびイミダゾ［１，５－ａ］ピラジン |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1406882A (en) * | 1972-04-28 | 1975-09-17 | Leo Pharm Prod Ltd | Benzoic acid derivatives and benzisptjoaup'e 1.1 dopxode derovatoves |
| JPS50157363A (es) * | 1974-06-06 | 1975-12-19 | ||
| US4166452A (en) * | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) * | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) * | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| WO1997028137A1 (en) * | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Heterocyclic derivatives as antidiabetic and antiobesity agents |
| US6090836A (en) * | 1996-02-02 | 2000-07-18 | Merck & Co., Inc. | Benzisoxazole-derived antidiabetic compounds |
| US6008237A (en) * | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
| CA2376919C (en) * | 1999-06-18 | 2008-11-04 | Merck & Co., Inc. | Arylthiazolidinedione and aryloxazolidinedione derivatives |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0002666D0 (en) * | 2000-02-04 | 2000-03-29 | Univ London | Blockade of voltage dependent sodium channels |
| JP2001288175A (ja) * | 2000-04-06 | 2001-10-16 | Nippon Soda Co Ltd | ヒドロキシベンゾイソオキサゾール化合物、製造方法、製造中間体、抗真菌薬および農園芸用殺菌剤 |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| DE10046029A1 (de) * | 2000-09-18 | 2002-03-28 | Bayer Ag | Indazole |
| EP1334094B1 (en) | 2000-11-02 | 2004-12-29 | F. Hoffmann-La Roche Ag | Cholesterol lowering benzo[b]thiophenes and benzo[d]isothiazoles |
| US6608409B2 (en) * | 2001-05-15 | 2003-08-19 | General Electric Company | High temperature super-conducting rotor having a vacuum vessel and electromagnetic shield and an assembly method |
| WO2002098860A1 (en) * | 2001-06-01 | 2002-12-12 | Alcon, Inc. | Novel fused indazoles and indoles and their use for the treatment of glaucoma |
| EP1403255A4 (en) | 2001-06-12 | 2005-04-06 | Sumitomo Pharma | INHIBITORS OF RHO KINASE |
| CZ2004359A3 (cs) * | 2001-09-26 | 2004-09-15 | Pharmacia Italia S.P.A. | Aminoindazolové deriváty aktivní jako inhibitory kinázy, způsob jejich přípravy a farmaceutické prostředky obsahující tyto deriváty |
| US6960607B2 (en) * | 2001-12-13 | 2005-11-01 | Wyeth | Naphthyl benzoxazoles and benzisoxazoles as estrogenic agents |
| US6884814B2 (en) * | 2001-12-13 | 2005-04-26 | Wyeth | Phenyl benzisoxazoles as estrogenic agents |
| US7104676B2 (en) * | 2002-04-15 | 2006-09-12 | K.W. Muth Company, Inc. | Signaling assembly |
| WO2003101968A1 (fr) * | 2002-05-31 | 2003-12-11 | Eisai Co., Ltd. | Compose de pyrazole et composition medicinale le contenant |
| TW200400177A (en) * | 2002-06-04 | 2004-01-01 | Wyeth Corp | 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
| CN1678589A (zh) * | 2002-09-05 | 2005-10-05 | 安万特医药股份有限公司 | 作为药物的新氨基吲唑衍生物与含有它们的药物组合物 |
| TW200409759A (en) * | 2002-09-25 | 2004-06-16 | Wyeth Corp | Substituted 4-(indazol-3-yl)phenols |
| US7196082B2 (en) * | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| JP2006510742A (ja) | 2002-11-08 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 高眼圧治療用眼科組成物 |
| MXPA05005554A (es) * | 2002-12-12 | 2005-07-26 | Aventis Pharma Sa | Derivados de aminoindazol y su utilizacion como inhibidores de quinasas. |
| WO2004078116A2 (en) * | 2003-03-03 | 2004-09-16 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US7592494B2 (en) * | 2003-07-25 | 2009-09-22 | Honeywell International Inc. | Process for the manufacture of 1,3,3,3-tetrafluoropropene |
| DE10339719A1 (de) * | 2003-08-28 | 2005-03-24 | BSH Bosch und Siemens Hausgeräte GmbH | Blähkörper zum Trocknen und/oder Glätten von Kleidungsstücken |
| FR2864084B1 (fr) | 2003-12-17 | 2006-02-10 | Aventis Pharma Sa | Nouveaux derives organophosphores des indazoles et leur utilisation comme medicaments |
| RU2006134022A (ru) * | 2004-02-27 | 2008-04-10 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные индазола и содержащие их фармацевтические композиции |
| CN101027053A (zh) * | 2004-07-27 | 2007-08-29 | 诺瓦提斯公司 | Hsp90抑制剂 |
| EP1647549A1 (en) * | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents |
-
2004
- 2004-10-14 EP EP04292439A patent/EP1647549A1/en not_active Withdrawn
-
2005
- 2005-10-14 SG SG201000276-4A patent/SG158886A1/en unknown
- 2005-10-14 AP AP2007003960A patent/AP2007003960A0/xx unknown
- 2005-10-14 ES ES05794749T patent/ES2368203T3/es active Active
- 2005-10-14 CA CA2582180A patent/CA2582180C/en not_active Expired - Fee Related
- 2005-10-14 KR KR1020077007907A patent/KR20070109976A/ko not_active Application Discontinuation
- 2005-10-14 EP EP05794749A patent/EP1812404B1/en not_active Not-in-force
- 2005-10-14 WO PCT/EP2005/055262 patent/WO2006040351A1/en active Application Filing
- 2005-10-14 AU AU2005293509A patent/AU2005293509B2/en not_active Ceased
- 2005-10-14 BR BRPI0516851-1A patent/BRPI0516851A/pt not_active IP Right Cessation
- 2005-10-14 CN CN2005800430259A patent/CN101080395B/zh not_active Expired - Fee Related
- 2005-10-14 US US11/664,887 patent/US7977364B2/en not_active Expired - Fee Related
- 2005-10-14 JP JP2007536185A patent/JP5047801B2/ja not_active Expired - Fee Related
- 2005-10-14 AT AT05794749T patent/ATE512952T1/de not_active IP Right Cessation
- 2005-10-14 MX MX2007004372A patent/MX2007004372A/es active IP Right Grant
- 2005-10-14 RU RU2007117714/04A patent/RU2402536C2/ru not_active IP Right Cessation
- 2005-10-14 AR ARP050104313A patent/AR051457A1/es not_active Application Discontinuation
- 2005-10-14 UA UAA200704016A patent/UA90280C2/ru unknown
- 2005-10-14 ZA ZA200702690A patent/ZA200702690B/xx unknown
- 2005-10-14 NZ NZ554279A patent/NZ554279A/en not_active IP Right Cessation
- 2005-10-14 TW TW094136060A patent/TW200619202A/zh unknown
-
2007
- 2007-03-20 IL IL182047A patent/IL182047A/en not_active IP Right Cessation
- 2007-04-09 MA MA29816A patent/MA28928B1/fr unknown
- 2007-04-13 TN TNP2007000138A patent/TNSN07138A1/fr unknown
- 2007-04-16 NO NO20071922A patent/NO20071922L/no not_active Application Discontinuation
-
2011
- 2011-06-03 US US13/152,433 patent/US8173679B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051457A1 (es) | Indazoles, benzisoxazoles y benzisotiazoles, procedimiento para prepararlos, composiciones farmaceuticas y su uso como agentes estrogenicos | |
| AR054799A1 (es) | Derivados de oxindol | |
| ECSP066695A (es) | Derivados de n-(1,5-difenil-1h-pirazol-3-il) sulfonamida con afinidad por los receptores cb1 | |
| AR091176A1 (es) | Pirrodilina-2-carboxamidas sustituidas | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
| AR060590A1 (es) | Compuestos imidazo | |
| AR054365A1 (es) | Derivados de heteroaril benzamidas, composiciones farmaceuticas que los contienen, usos en enfermedades mediadas por glucoquinasasy metodo de preparacion de los mismos. | |
| MXPA05006908A (es) | Compuestos diazoicos cationicos particulares, composiciones que los contienen como colorante directo, procedimiento de coloracion de fibras queratinicas y dispositivo. | |
| AR087182A1 (es) | DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| AR048521A1 (es) | Derivados sustituidos de diaza-espiro-(4.5)-decano y su uso como antagonistas de neuroquininas | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| AR056195A1 (es) | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos | |
| AR047890A1 (es) | Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3 | |
| AR056979A1 (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| AR053712A1 (es) | Heteroarilos sustituidos, antagonistas de cb1 (receptor 1 canabinoide) | |
| CO5680438A2 (es) | Uso de derivados de ciclotiocarbamato en tratamiento de condiciones relacionadas con hormonas | |
| AR062360A1 (es) | Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa | |
| AR054790A1 (es) | Metodos para el tratamiento de disfuncion sexual | |
| AR061134A1 (es) | Derivados de tioxantina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |